Krystal Biotech (KRYS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.79
- EPS estimate
- $1.70
- EPS surprise
- +5.23%
- Revenue surprise
- −1.41%
- Revenue
- $119.2M
- Revenue estimate
- $120.9M
- Reported
- Aug 3, 2026
Krystal Biotech reported Q2 2026 results on August 3, 2026. Earnings per share came in at $1.79, ahead of the $1.70 estimate by 5.23%. Revenue was $119.2 million, 1.41% short of the $120.9 million consensus. Compared with Q2 2025, EPS rose about 39% from $1.29 and revenue rose about 24% from $96.0 million.
The table traces a move from losses to steady profits. Every quarter from Q3 2021 through Q2 2023 was a loss, with no revenue recorded. Revenue first appears in Q3 2023 at $8.6 million and has grown in nearly every quarter since, reaching a high in the table in Q2 2026. Annual EPS went from a loss of $5.51 in 2022 to $0.08 in 2023, $2.99 in 2024 and $6.85 in 2025. The first half of 2026 totals $3.62, about 45% above the same period of 2025. The highest quarterly EPS was $2.79 in Q3 2023. Over the last 20 quarters, the company beat the EPS estimate 12 times.
Krystal Biotech reported its third quarter in the first week of November in each year shown. That points to early November 2026 for the Q3 2026 report, which will show whether revenue keeps rising above Q2's level.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 3, 2026 | $1.70 | $1.79 | +5.23% | $119.2M | SEC |
| Q1 2026 | May 4, 2026 | $1.49 | $1.83 | +22.80% | $116.4M | SEC |
| Q4 2025 | Feb 17, 2026 | $1.57 | $1.70 | +8.49% | $107.1M | SEC |
| Q3 2025 | Nov 3, 2025 | $1.09 | $2.66 | +144.13% | $97.8M | SEC |
| Q2 2025 | Aug 4, 2025 | $1.18 | $1.29 | +8.88% | $96.0M | SEC |
| Q1 2025 | May 6, 2025 | $1.43 | $1.20 | −15.89% | $88.2M | SEC |
| Q4 2024 | Feb 19, 2025 | $1.18 | $1.52 | +28.37% | $91.1M | SEC |
| Q3 2024 | Nov 4, 2024 | $0.99 | $0.91 | −8.40% | $83.8M | SEC |
| Q2 2024 | Aug 5, 2024 | $0.73 | $0.53 | −27.68% | $70.3M | SEC |
| Q1 2024 | May 6, 2024 | $0.27 | $0.03 | −88.73% | $45.3M | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.31 | $0.30 | +197.31% | $42.1M | SEC |
| Q3 2023 | Nov 6, 2023 | −$1.20 | $2.79 | +332.27% | $8.6M | SEC |
| Q2 2023 | Aug 7, 2023 | −$1.27 | −$1.25 | +1.19% | $0.00 | SEC |
| Q1 2023 | May 8, 2023 | −$1.44 | −$1.76 | −22.35% | $0.00 | SEC |
| Q4 2022 | Feb 27, 2023 | −$1.26 | −$1.25 | +0.70% | $0.00 | SEC |
| Q3 2022 | Nov 7, 2022 | −$1.19 | −$1.17 | +1.47% | $0.00 | SEC |
| Q2 2022 | Aug 8, 2022 | −$1.03 | −$1.10 | −7.18% | $0.00 | SEC |
| Q1 2022 | May 9, 2022 | −$0.92 | −$1.99 | −116.99% | $0.00 | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.72 | −$0.94 | −29.96% | $0.00 | SEC |
| Q3 2021 | Nov 8, 2021 | −$0.76 | −$0.70 | +7.75% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Krystal Biotech (KRYS) last report earnings?
Krystal Biotech last reported on Aug 3, 2026, covering fiscal Q2 2026.
Did KRYS beat earnings estimates?
Yes. Krystal Biotech reported EPS of $1.79 for Q2 2026 against a $1.70 estimate — a 5.23% beat.
How much revenue did KRYS report last quarter?
Krystal Biotech reported $119.2M in revenue for Q2 2026, against a consensus estimate of $120.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.